DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability

IF 6.9 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Oncogene Pub Date : 2024-09-17 DOI:10.1038/s41388-024-03162-6

Yunshu Shi, Junyong Wang, Qiang Yuan, Yingying Chen, Miao Zhao, Xiaoyu Li, Zitong Wang, Hao Zhou, Fangli Zhu, Bing Wei, Yanan Jiang, Jimin Zhao, Yan Qiao, Zigang Dong, Kangdong Liu

{"title":"DDX5 promotes esophageal squamous cell carcinoma growth through sustaining VAV3 mRNA stability","authors":"Yunshu Shi, Junyong Wang, Qiang Yuan, Yingying Chen, Miao Zhao, Xiaoyu Li, Zitong Wang, Hao Zhou, Fangli Zhu, Bing Wei, Yanan Jiang, Jimin Zhao, Yan Qiao, Zigang Dong, Kangdong Liu","doi":"10.1038/s41388-024-03162-6","DOIUrl":null,"url":null,"abstract":"Novel therapeutic targets and their inhibitors for esophageal squamous cell carcinoma (ESCC) prevention and therapy are urgently needed. This study aimed to investigate the function of DEAD-box helicase 5 (DDX5) in ESCC progression and to identify a promising inhibitor of DDX5. We verified that DDX5 was highly expressed in ESCC and played an oncogenic role, binding with vav guanine nucleotide exchange factor 3 (VAV3) mRNA and facilitating VAV3 mRNA N6-methyladenosine (m6A) modification by interacting with the m6A methyltransferase 3 (METTL3). M6A-modified VAV3 mRNA was identified by insulin-like growth factor 1 (IGF2BP1), increasing mRNA stability. Methylnissolin-3-β-D-O-glucoside (MD) inhibited ESCC progression through the DDX5-VAV3 axis. Our findings suggest that DDX5 promotes ESCC progression. MD inhibits ESCC progression by targeting DDX5.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"43 44","pages":"3240-3254"},"PeriodicalIF":6.9000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41388-024-03162-6.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogene","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41388-024-03162-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Novel therapeutic targets and their inhibitors for esophageal squamous cell carcinoma (ESCC) prevention and therapy are urgently needed. This study aimed to investigate the function of DEAD-box helicase 5 (DDX5) in ESCC progression and to identify a promising inhibitor of DDX5. We verified that DDX5 was highly expressed in ESCC and played an oncogenic role, binding with vav guanine nucleotide exchange factor 3 (VAV3) mRNA and facilitating VAV3 mRNA N6-methyladenosine (m6A) modification by interacting with the m6A methyltransferase 3 (METTL3). M6A-modified VAV3 mRNA was identified by insulin-like growth factor 1 (IGF2BP1), increasing mRNA stability. Methylnissolin-3-β-D-O-glucoside (MD) inhibited ESCC progression through the DDX5-VAV3 axis. Our findings suggest that DDX5 promotes ESCC progression. MD inhibits ESCC progression by targeting DDX5.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

DDX5 通过维持 VAV3 mRNA 的稳定性促进食管鳞状细胞癌的生长

食管鳞状细胞癌（ESCC）的预防和治疗迫切需要新的治疗靶点及其抑制剂。本研究旨在研究DEAD-box螺旋酶5（DDX5）在ESCC进展中的功能，并找出一种有前景的DDX5抑制剂。我们证实，DDX5在ESCC中高表达，并发挥致癌作用，它与VAV鸟嘌呤核苷酸交换因子3（VAV3）mRNA结合，并通过与m6A甲基转移酶3（METTL3）相互作用促进VAV3 mRNA的N6-甲基腺苷（m6A）修饰。经 M6A 修饰的 VAV3 mRNA 被胰岛素样生长因子 1（IGF2BP1）识别，从而增加了 mRNA 的稳定性。甲基尼索林-3-β-D-O-葡萄糖苷（MD）通过DDX5-VAV3轴抑制了ESCC的进展。我们的研究结果表明，DDX5会促进ESCC的进展。MD通过靶向DDX5抑制ESCC的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncogene 医学-生化与分子生物学

CiteScore

15.30

自引率

1.20%

发文量

404

审稿时长

1 months

期刊介绍： Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge. Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.